

Alan N Baer

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1602072/alan-n-baer-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

67
papers

1,803
citations

24
h-index

41
g-index

76
ext. papers

2,310
ext. citations

4.9
avg. IF

4.98
L-index

#	Paper	IF	Citations
67	A comprehensive overview of living with Sjögren's: results of a National Sjögren's Foundation survey.. <i>Clinical Rheumatology</i> , 2022 , 1	3.9	0
66	A New Screening Questionnaire to Identify Patients With Dry Eye With a High Likelihood of Having Sjögren Syndrome. <i>Cornea</i> , 2021 , 40, 179-187	3.1	3
65	National Sjögren's Foundation Survey: Burden of Oral and Systemic Involvement on Quality of Life. <i>Journal of Rheumatology</i> , 2021 , 48, 1029-1036	4.1	1
64	Antibodies to both Ro52 and Ro60 may identify Sjögren's syndrome patients best suited for clinical trials of disease-modifying therapies. <i>Arthritis Care and Research</i> , 2021 ,	4.7	4
63	Risk Factors For Infection And Health Impacts Of The Covid-19 Pandemic In People With Autoimmune Diseases. <i>Clinical Infectious Diseases</i> , 2021 ,	11.6	7
62	Sjögren's Disease, Not Syndrome. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1347-1348	9.5	4
61	Ultrasound-Guided Biopsy of Suspected Salivary Gland Lymphoma in Sjögren's Syndrome. <i>Arthritis Care and Research</i> , 2021 , 73, 849-855	4.7	5
60	Sicca Syndromes 2021 , 109-142		0
59	RISK FACTORS FOR INFECTION AND HEALTH IMPACTS OF THE COVID-19 PANDEMIC IN PEOPLE WITH AUTOIMMUNE DISEASES 2021 ,		2
58	Neuropathic Pain in the Eyes, Body, and Mouth: Insights from the Sjögren's International Collaborative Clinical Alliance. <i>Pain Practice</i> , 2021 , 21, 630-637	3	0
57	Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure. <i>Lancet Rheumatology, The</i> , 2021 , 3, e553-e562	14.2	6
56	Reply: Sjögren disease, not Sjögren's. <i>Arthritis and Rheumatology</i> , 2021 ,	9.5	
55	Hyperviscosity Syndrome in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2021 , 48, 788-789	4.1	3
54	Ocular Manifestations and Burden Related to Sjögren Syndrome: Results of a Patient Survey. <i>American Journal of Ophthalmology</i> , 2020 , 219, 40-48	4.9	11
53	Concurrent primary Sjögren's syndrome and isolated ocular sarcoidosis presenting with bilateral corneal scarring and dry eye. <i>American Journal of Ophthalmology Case Reports</i> , 2020 , 19, 100790	1.3	0
52	Toward better outcomes in Sjögren's syndrome: The promise of a stratified medicine approach. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020 , 34, 101475	5.3	8
51	Lymphoproliferative disease in Sjögren's syndrome 2020 , 129-152		

50	Extraglandular ocular involvement and morbidity and mortality in primary Sjögren's Syndrome. <i>PLoS ONE</i> , 2020 , 15, e0239769	3.7	4
49	Association of Sjögren's Syndrome With Reduced Lifetime Sex Hormone Exposure: A Case-Control Study. <i>Arthritis Care and Research</i> , 2020 , 72, 1315-1322	4.7	9
48	Unique Sjögren's syndrome patient subsets defined by molecular features. <i>Rheumatology</i> , 2020 , 59, 860-868	3.9	22
47	Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	22
46	How to treat Sjögren's syndrome. <i>Rheumatology</i> , 2019 ,	3.9	5
45	OP0039 EFFICACY AND SAFETY OF ABATACEPT IN ACTIVE PRIMARY SJÖGREN'S SYNDROME: RESULTS OF A RANDOMISED PLACEBO-CONTROLLED PHASE III TRIAL 2019 ,		2
44	Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy. <i>Oncologist</i> , 2019 , 24, 1259-1269	5.7	67
43	Prevalence of Novel Candidate Sjögren Syndrome Autoantibodies in the Penn Sjögren's International Collaborative Clinical Alliance Cohort. <i>Cornea</i> , 2019 , 38, 1500-1505	3.1	5
42	Biopsy-Proven Small-Fiber Neuropathy in Primary Sjögren's Syndrome: Neuropathic Pain Characteristics, Autoantibody Findings, and Histopathologic Features. <i>Arthritis Care and Research</i> , 2019 , 71, 936-948	4.7	16
41	Renal involvement in primary Sjögren's syndrome: natural history and treatment outcome. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37 Suppl 118, 123-132	2.2	6
40	By One's Own Hand. <i>Arthritis and Rheumatology</i> , 2018 , 70, 1529	9.5	0
39	Clinical Efficacy and Safety of Baminercept, a Lymphotoxin α Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2018 , 70, 1470-1480	9.5	35
38	Natural History and Predictors of Progression to Sjögren's Syndrome Among Participants of the Sjögren's International Collaborative Clinical Alliance Registry. <i>Arthritis Care and Research</i> , 2018 , 70, 284-294	4.7	27
37	Update on Sjögren Syndrome and Other Causes of Sicca in Older Adults. <i>Rheumatic Disease Clinics of North America</i> , 2018 , 44, 419-436	2.4	23
36	PHIP-Seq characterization of serum antibodies using oligonucleotide-encoded peptidomes. <i>Nature Protocols</i> , 2018 , 13, 1958-1978	18.8	51
35	Reply. <i>Arthritis Care and Research</i> , 2017 , 69, 454	4.7	
34	Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade. <i>Oncologist</i> , 2017 , 22, 627-630	5.7	49
33	Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 43-50	2.4	248

32	Salivary gland ultrasound abnormalities in primary Sjögren's syndrome: consensual US-SG core items definition and reliability. <i>RMD Open</i> , 2017 , 3, e000364	5.9	64
31	Sjögren Syndrome and Other Causes of Sicca in Older Adults. <i>Clinics in Geriatric Medicine</i> , 2017 , 33, 87-103	3.8	17
30	Significance and Implications of Patient-reported Xerostomia in Sjögren's Syndrome: Findings From the National Institutes of Health Cohort. <i>EBioMedicine</i> , 2016 , 12, 270-279	8.8	18
29	Association of Anticentromere Antibodies With More Severe Exocrine Glandular Dysfunction in Sjögren's Syndrome: Analysis of the Sjögren's International Collaborative Clinical Alliance Cohort. <i>Arthritis Care and Research</i> , 2016 , 68, 1554-9	4.7	28
28	Dual-energy computed tomography has limited sensitivity for non-tophaceous gout: a comparison study with tophaceous gout. <i>BMC Musculoskeletal Disorders</i> , 2016 , 17, 91	2.8	39
27	Cytosolic 5'-Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases. <i>Arthritis Care and Research</i> , 2016 , 68, 66-71	4.7	71
26	Searching for the Source: Bacteremia with Marked Cerebrospinal Fluid Pleocytosis. <i>American Journal of Medicine</i> , 2016 , 129, 44-7	2.4	0
25	PUF60: a prominent new target of the autoimmune response in dermatomyositis and Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1145-51	2.4	28
24	A validated method of labial minor salivary gland biopsy for the diagnosis of Sjögren's syndrome. <i>Laryngoscope</i> , 2016 , 126, 2041-6	3.6	9
23	Association of Antibodies to Interferon-Inducible Protein-16 With Markers of More Severe Disease in Primary Sjögren's Syndrome. <i>Arthritis Care and Research</i> , 2016 , 68, 254-60	4.7	27
22	Ocular complications of primary Sjögren syndrome in men. <i>American Journal of Ophthalmology</i> , 2015 , 160, 447-452.e1	4.9	21
21	Molecular Subsetting of Interferon Pathways in Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2015 , 67, 2437-46	9.5	86
20	The SSB-positive/SSA-negative antibody profile is not associated with key phenotypic features of Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1557-61	2.4	56
19	Ocular and systemic morbidity in a longitudinal cohort of Sjögren's syndrome. <i>Ophthalmology</i> , 2015 , 122, 56-61	7.3	58
18	Sjögren syndrome 2015 , 1131-1143		
17	Rare diagnosis of IgG4-related systemic disease by lip biopsy in an international Sjögren syndrome registry. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2013 , 115, e34-9	2	26
16	Noninflammatory myopathies. <i>Rheumatic Disease Clinics of North America</i> , 2013 , 39, 457-79	2.4	7
15	Flares of systemic lupus erythematosus during pregnancy and the puerperium: prevention, diagnosis and management. <i>Expert Review of Clinical Immunology</i> , 2012 , 8, 439-53	5.1	67

14	Primary Sjögren's syndrome as a systemic disease: a study of participants enrolled in an international Sjögren's syndrome registry. <i>Arthritis Care and Research</i> , 2012 , 64, 911-8	4.7	116
13	Paraneoplastic muscle disease. <i>Rheumatic Disease Clinics of North America</i> , 2011 , 37, 185-200, v-vi	2.4	11
12	Lupus and pregnancy. <i>Obstetrical and Gynecological Survey</i> , 2011 , 66, 639-53	2.4	72
11	Malignancy in myositis. <i>Current Rheumatology Reports</i> , 2011 , 13, 208-15	4.9	110
10	Dr. Baer, et al reply. <i>Journal of Rheumatology</i> , 2011 , 38, 393.2-393	4.1	
9	Secondary Sjogren's syndrome in systemic lupus erythematosus defines a distinct disease subset. <i>Journal of Rheumatology</i> , 2010 , 37, 1143-9	4.1	53
8	The Risk of Malignancy in Patients with Dermatomyositis and Polymyositis 2009 , 307-318		1
7	Breaking bad news: use of cancer survivors in role-playing exercises. <i>Journal of Palliative Medicine</i> , 2008 , 11, 885-92	2.2	28
6	Myotoxicity associated with lipid-lowering drugs. <i>Current Opinion in Rheumatology</i> , 2007 , 19, 67-73	5.3	59
5	Differential diagnosis of idiopathic inflammatory myopathies. <i>Current Rheumatology Reports</i> , 2006 , 8, 178-87	4.9	19
4	Advances in the therapy of idiopathic inflammatory myopathies. <i>Current Opinion in Rheumatology</i> , 2006 , 18, 236-41	5.3	8
3	Acute myeloid leukemia in the setting of low dose weekly methotrexate therapy for rheumatoid arthritis. <i>Leukemia and Lymphoma</i> , 2001 , 42, 371-8	1.9	8
2	Erythropoietin response to anemia as a function of age. <i>Journal of the American Geriatrics Society</i> , 1991 , 39, 30-2	5.6	32
1	Estrogen metabolism in the (New Zealand black x New Zealand white)F1 murine model of systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1990 , 33, 107-12		7